Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bydureon in Type 2 Diabetes and Type 4 Cardiorenal Syndrome
NCT02251431Phase 3Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Nov 2015
- Primary completion
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) and cardiorenal syndrome (CRS), sponsored by Baylor Scott & White Research Institute. Started Nov 2015; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NCT02251431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251431.